ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

摘要:

The influenza virus enzyme neuraminidase is an attractive antiviral target because its active site is highly conserved among many influenza A and B strains. Neuraminidase inhibitors are an exciting new class of antiviral drug that should help in the prevention and treatment of influenza infection. Encouraging new clinical data on the 2 most advanced neuraminidase inhibitors, GS-4104 and zanamivir, were presented at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy [San Diego, US; September 1998]. These data suggest that both agents could be useful in the prophylaxis and treatment of influenza A and B.

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

摘要:

Limited clinical evidence supports the use of IV alteplase as thrombolytic therapy for patients with acute ischaemic stroke. Results from the US National Institute of Neurological Disorders and Stroke (NINDS) trial indicated that IV alteplase 0.9 mg/kg improved patient outcome when administered within 3 hours of onset of stroke symptoms.*Nevertheless, further clinical data are needed to support the European licensing of alteplase in this indication. The first large multicentre European Cooperative Acute Stroke Study (ECASS I) failed to demonstrate a significant treatment benefit of alteplase compared with placebo in terms of the primary outcome measures.**However, a per-protocol target population analysis of ECASS I showed significant differences in favour of alteplase. Nevertheless, mortality was also increased. It was hoped that a second European study (ECASS II) would help provide a definitive answer to the question of whether early treatment with alteplase is beneficial in stroke. Unfortunately, the neutral results of ECASS II fail to definitively prove the case for alteplase therapy for patients with acute ischaemic stroke, delegates were told at the third Congress of the European Federation of Neurological Societies [Seville, Spain; September 1998].

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS